Shares of Fortress Biotech Inc. (FBIO) are rising over 17% in pre-market today, after the company announced that its partner company Oncogenuity Inc. has entered into an exclusive worldwide licensing agreement with Columbia University to develop novel oligonucleotides for the treatment of genetically driven cancers.
The proprietary platform produces oligomers, now known as "ONCOlogues," that are capable of binding gene sequences 1,000 times more effectively than complementary native DNA.
The stock has been trading in the range of $1.0400 - $3.1100 for the past one year, and closed Thursday's trade at $2.09, down 3 cents or 1.42%. FBIO is currently trading at $2.45, up 36 cents or 17.22% in the pre-market trading session.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.